Cannabis Science Inc (fka CBIS)

[earlylight]

Cannabis Science Acquires the Kaneabis Brands, Which Includes the
Kaneabis Fund, the Kaneabis Report, Kaneabis Radio, Kaneabis Consulting, and
Robert Kane Partners


COLORADO SPRINGS, Colo., Mar 21, 2012 (BUSINESS WIRE) -- Cannabis Science, Inc.
(OTCBB:CBIS.ob - News), a pioneering US biotech company developing
pharmaceutical cannabis products, is pleased to announce its acquisition of The
Kaneabis Brand through its parent company Cannabis Consulting Inc. Cannabis
Science is also proud to announce that Robert Kane has been promoted to the
position of Vice President of Investor Relations, Mr. Robert Kane is in the
process of relocating to Colorado Springs to help facilitate opening up the new
Cannabis Science headquarters in Colorado Springs, Colorado.

Cannabis Science embraces Mr. Kane and his Kaneabis Brand. Each one of Mr.
Kane's endeavors falls directly in line with Cannabis
Science’s mission to establish the Medical Cannabis
Industry as a viable pharmaceutical/nutraceutical business model and investment
alternative for all investors.

For over a decade Robert J. Kane worked for Stifel Nicolaus (NYSE: SF) as a
registered representative. Recognizing the Medical Cannabis
Industry’s opportunity Mr. Kane left Stifel Nicolaus
and began consulting Medical Cannabis Industry leaders mostly with business
plans to support investment in the industry, and the Kaneabis brand was born.
Today, Mr. Kane, along with Cannabis Science, will educate conservative Wall
Street that Cannabis is a viable alternative investment opportunity that will
also help improve the health of mankind.

This Cannabis Science acquisition includes but not limited to;

a. All contracted rights, properties, patents, trademarks, and distribution
rights and agreements pertaining to its Cannabis Consulting Inc.

b. Robert Kane Partners

c. Kaneabis Consulting

d. Kaneabis Fund

e. Kaneabis Report

f. Kaneabis Radio

Dr. Robert Melamede Ph.D., Cannabis Science President & CEO, stated,
“For the last 6 months we have been working with Mr.
Kane on a consulting basis and have been extremely pleased with his work ethic,
expertise, and dedication to promoting the global 'cannabis awakening'. We have
received a lot of positive feedback from shareholders, and we believe bringing
Mr. Kane and his resources exclusively into the Cannabis Science business model
is a good decision. It will better serve the needs of our shareholders and add
additional revenue to our bottom line through the expanded line of services that
we can now offer. These revenues, along with revenues generated from our other
profit centers, should improve our balance sheet and give us access to the
additional capital required to complete the FDA approval
process.”

ABOUT ROBERT KANE

Robert Kane’s professional career begins with a
nomination by the Somerset County, New Jersey Chamber of Commerce for
"Outstanding Business Person of the Year" at the age of 16. Inspired and
ambitious, Mr. Kane then earned the "Isabella Cannon Leadership Scholarship,"
and attended Elon University, North Carolina.

Robert’s early focus and expertise was in sales, as
he was a Thomas Nelson bookman in college spending a college summer selling
books and bibles door to door in Georgia through the college internship program
with Thomas Nelson Corporation (Nashville, TN). These sales talents earned
Robert success in many businesses from his uncles jewelry store Roy T Jewelers
(Piscataway, NJ), a Board Member of an Executive Fitness Club, and as a mortgage
broker between college and when he first started at Ryan, Beck & Company, which
eventually became Stifel Nicolaus (NYSE: SF).

Mr. Kane acted as Chairman of the Board for the Write Note foundation, as well
as served on the board of the National Single Parent Resource Center. He served
on the organizational committee for the Pajama Program -- which was once
featured on Oprah - and has participated in many charity events including a
“Walk a Mile in Her Shoes”
for the International Women's Domestic Abuse Council.

Eternally observing for new investment prospects, Robert then focused his
attention on an emerging Cannabis Industry. After serving 11 years as a
registered representative with Stifel Nicolaus (NYSE:SF), Robert established
Cannabis Consulting Inc., at the dawn of 2010.

Mesmerized by the sheer potential of the burgeoning Cannabis Industry, Robert
set out on a speaking tour, initially funded with a small loan from a family
member and the supported operationally with the writing of business plans, sales
consulting, and investor relations. Robert’s breaks
in the industry was through participating as a panelist in the Los Angeles
Medical Marijuana Expo, Hawaii's First Medical Marijuana Conference, KushCon II
in Denver, The Marijuana Conference in San Francisco, New Jersey's 1st Cannabis
Expo, and the Green Relief Expo. He sheds new light on an industry caught in a
grey area; he is a leading proponent for introducing would-be investors to one
of the most flourishing industries since the invention of the smart phone.

Robert Kane has written articles for Cannabis Times and MJ Business Daily.
Robert was a joint host with Casper Leitch in Time4Hemp
‘Taxing
Monday’s” in support of
the organization 280e Reform. www.280ereform.org.

Robert established the Medical Cannabis Index nicknamed the MCANI, and
blueprinted a private equity fund, The Kaneabis Fund which drew the attention of
the Wall Street Journal
http://online.wsj.com/article/SB10001424052748704677404576285011036650834.html

As Medical Cannabis continues spreading from one state to the next, Robert
continues offering a viable investment alternative for the more courageous and
daring investors.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical
marijuana research and development. The Company works with world authorities on
phytocannabinoid science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize phytocannabinoid-based
pharmaceutical products. In sum, we are dedicated to the creation of
cannabis-based medicines, both with and without psychoactive properties, to
treat disease and the symptoms of disease, as well as for general health
maintenance.

Forward Looking Statements; This Press Release includes forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing works such as
"anticipate," "seek," intend," "believe," "plan," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Some
or all of the events or results anticipated by these forward-looking statements
may not occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of competition, and the
Company's reliance on existing regulations regarding the use and development of
cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor
does it intend to update the results of these forward-looking statements.

SOURCE: Cannabis Science, Inc.



CONTACT:
Cannabis Science
Dr. Robert Melamede, 1-888-889-0888
President
[e-mail]
or
Robert Kane, 561-234-6929
Investor Relations
[e-mail]




Copyright Business Wire 2012

-0-




KEYWORD: United States

North America

Colorado

INDUSTRY KEYWORD: Health

Alternative Medicine

Biotechnology

Oncology

Pharmaceutical

Research

Science

SUBJECT CODE: Merger/Acquisition